Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Conditions
- Non-small Cell Lung Cancer
- Histiocytic Neoplasm
- Histiocytosis
- BRAF Gene Mutation
- BRAF V600E
- BRAF V600 Mutation
- BRAF Mutation-Related Tumors
- BRAF
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- Recurrent Lung Cancer
- Recurrent Lung Non-Small Cell Carcinoma
- NSCLC
- Solid Tumor
- Solid Carcinoma
- KRAS G12D
- KRAS G12V
- KRAS Mutation-Related Tumors
- NRAS Gene Mutation
- Thyroid Cancer
- Thyroid Carcinoma
- Colorectal Cancer
- Colorectal Carcinoma
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Brain Metastases
- Recurrent NSCLC
- KRAS G13C
- Acquired Resistance to KRAS G12C Inhibitor
- KRAS G12A
- KRAS G12F
- KRAS G12R
- KRAS G13D
Interventions
- DRUG: S241656
- DRUG: FOLFOX6/FOLFOX7
- DRUG: FOLFIRI
- DRUG: Cetuximab
- DRUG: Panitumumab
- DRUG: Gemcitabine
- DRUG: Nab-paclitaxel
Sponsor
Institut de Recherches Internationales Servier